

Maelor plc

AGM Statement

5 September 2007: Maelor plc (“Maelor” or the “Company”, AIM: MLR), the specialist hospital medicines business, is today providing the following update on current trading at its Annual General Meeting:

“In June we announced the Company’s results for the financial year ended 31 March 2007 and noted that it had been a year of significant achievements for Maelor. Under the leadership of our CEO, Tim Wright, we transformed Maelor into a profitable business with a focus on late stage specialist hospital medicines, leveraging our expertise in both pharmaceuticals and medical devices.

This progress has continued into the current financial year with the Company maintaining its strategy and delivering encouraging trading in line with the board’s expectations.

Since the year end we announced the transforming and synergistic acquisition of Acorus Therapeutics Limited (“Acorus”), a specialist pharmaceuticals and medical devices company. The acquisition has created a strong, enlarged Group. We have successfully completed the integration of the Acorus business into our portfolio and some of the immediate benefits of this will be reflected in the forthcoming interim accounts for the period ending 30 September 2007.

At the same time as developing market opportunities for our increased range of products both in the UK and overseas, we are aggressively pursuing our plans to grow the enlarged portfolio through direct promotion and effective partnerships. In addition to this, in line with our strategic ambitions, we are actively seeking to develop the Company through further acquisitions.”

Enquiries:

Financial Dynamics Limited +44(0) 20 7831 3113

Billy Clegg / Edward Westropp

Noble & Company Limited +44(0) 20 7763 2200

Matthew Hall/Sam Reynolds

Maelor plc +44(0) 1244 625150

Tim Wright

END